Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

Laura M. Tidmorea Department of Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA

https://orcid.org/0000-0002-3968-6981

Shellie L. Keastb Government Human Services Consulting, Mercer LLC, Phoenix, AZ, USA

Heidi C. Watersc Health Outcomes, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

Kristin L. Parejac Health Outcomes, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

Terry Cothrand Department of Pharmacy, Oklahoma Health Care Authority, Oklahoma City, OK, USA

Grant H. Skrepneka Department of Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, OK, USACorrespondence[email protected]

https://orcid.org/0000-0002-8563-8921

Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date